Aprea Therapeutics (NASDAQ:APRE) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a report published on Monday,Benzinga reports. The brokerage currently has a $20.00 price objective on the stock. HC Wainwright also issued estimates for Aprea Therapeutics’ Q4 2024 earnings at ($0.54) EPS, FY2024 earnings at ($2.39) EPS, FY2025 earnings at ($0.95) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.61) EPS.

Separately, Wedbush reissued an “outperform” rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Aprea Therapeutics Stock Performance

APRE stock opened at $2.92 on Monday. The stock’s 50 day simple moving average is $3.31 and its 200 day simple moving average is $3.84. Aprea Therapeutics has a fifty-two week low of $2.15 and a fifty-two week high of $8.85. The company has a market cap of $15.87 million, a P/E ratio of -1.04 and a beta of 0.97.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.11. The firm had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.45 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. Equities analysts predict that Aprea Therapeutics will post -2.55 earnings per share for the current year.

Insider Activity at Aprea Therapeutics

In other news, Director Bernd R. Seizinger acquired 10,000 shares of Aprea Therapeutics stock in a transaction on Friday, October 11th. The stock was acquired at an average cost of $2.68 per share, with a total value of $26,800.00. Following the completion of the acquisition, the director now owns 44,730 shares in the company, valued at approximately $119,876.40. This trade represents a 28.79 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Marc Duey sold 6,462 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $4.58, for a total value of $29,595.96. Following the transaction, the director now directly owns 233,651 shares of the company’s stock, valued at approximately $1,070,121.58. This trade represents a 2.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders acquired 42,290 shares of company stock valued at $165,096. 12.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Stonepine Capital Management LLC purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics accounts for approximately 0.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st largest position. Stonepine Capital Management LLC owned approximately 2.53% of Aprea Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.